Evelo Biosciences, Inc. (EVLO): Price and Financial Metrics


Evelo Biosciences, Inc. (EVLO): $5.24

0.03 (+0.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EVLO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 453

in industry

EVLO Stock Price Chart Interactive Chart >

Price chart for EVLO

EVLO Price/Volume Stats

Current price $5.24 52-week high $19.93
Prev. close $5.21 52-week low $4.65
Day low $5.12 Volume 93,162
Day high $5.33 Avg. volume 240,222
50-day MA $7.31 Dividend yield N/A
200-day MA $9.89 Market Cap 280.13M

Evelo Biosciences, Inc. (EVLO) Company Bio


Evelo Biosciences, Inc. focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn’s colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is based in Cambridge, Massachusetts.


EVLO Latest News Stream


Event/Time News Detail
Loading, please wait...

EVLO Latest Social Stream


Loading social stream, please wait...

View Full EVLO Social Stream

Latest EVLO News From Around the Web

Below are the latest news stories about Evelo Biosciences Inc that investors may wish to consider to help them evaluate EVLO as an investment opportunity.

Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January

Yahoo | January 17, 2022

Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced its strategic priorities and upcoming catalysts for 2022. “In 2021 we announced positive Phase 2 clinical data for our first SINTAX-based medicine EDP1815 in psoriasis, demonstrating that EDP1815 is a potential medicine that can be delivered orally t

Yahoo | January 4, 2022

Evelo Biosciences picked for addition to Nasdaq Biotechnology Index

No summary available.

Seeking Alpha | December 14, 2021

Evelo Biosciences Added to Nasdaq Biotechnology Index

CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the Company has been added to the NASDAQ Biotechnology Index ® (Nasdaq: NBI), effective prior to market open on December 20, 2021.

Intrado Digital Media | December 14, 2021

Goldman Sachs Group Inc. Purchases 12,716 Shares of Evelo Biosciences, Inc. (NASDAQ:EVLO)

Goldman Sachs Group Inc. boosted its position in shares of Evelo Biosciences, Inc. (NASDAQ:EVLO) by 90.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,779 shares of the companys stock after purchasing an additional 12,716 shares during the quarter. Goldman Sachs Group Inc.s holdings []

Transcript Daily | December 9, 2021

Read More 'EVLO' Stories Here

EVLO Price Returns

1-mo -23.50%
3-mo -36.64%
6-mo -43.11%
1-year -67.95%
3-year -39.21%
5-year N/A
YTD -13.67%
2021 -49.79%
2020 197.78%
2019 -68.79%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8905 seconds.